In pancreatic cancer, loss of MSI2 has been shown to lead to a defect in progression from PanIN to adenocarcinoma (Fox et al., 2016), exerting its impact through powerful oncogenes such as Met and epigenetic regulators such as BRD4 and HMGB2. This evidence concerns the gene MSI2 and pancreatic neoplasm.